ALPK3 Truncating Variants Cause Autosomal Dominant Hypertrophic Cardiomyopathy
|
By LabMedica International staff writers Posted on 07 Oct 2021 |

Image: The SureSelect Target Enrichment System is a highly efficient hybrid selection technique for optimizing next-generation sequencing (Photo courtesy of Agilent Technologies)
In hypertrophic cardiomyopathy, heart muscles are thicker, which can make it harder for the heart to receive and pump blood. While in most cases the condition will not affect daily life, it can cause heart failure and is frequently cited as the most common cause of sudden unexpected death in young people.
Hypertrophic cardiomyopathy (HCM) is a genetic condition caused by a change or mutation in one or more genes and is passed on through families. A child of someone with HCM has a 50% chance of inheriting the condition. Most people with HCM have no symptoms or feel stable throughout their life. However, others do have symptoms. Some people find that their symptoms worsen in later life. This may be because their heart muscle has slowly become stiffer, making it harder for the heart to pump.
A large team of international scientists led by those at the University College London (London, UK) analyzed the genomes of 2,817 people with hypertrophic cardiomyopathy referred from centers in Spain, the UK, Denmark, Russia, Latvia, Brazil, and Argentina. The discovery cohort comprised 770 consecutively evaluated unrelated patients with HCM. The aim of their study was to determine the frequency of heterozygous truncating alpha-protein kinase (ALPK3) variants (ALPK3tv) in patients with HCM and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies.
From 2018 to 2020, ALPK3 was sequenced using next-generation sequencing in 4,904 consecutive unrelated probands with inherited cardiac conditions referred for molecular genetic diagnosis. Coding exons and intronic boundaries of 261 genes related to inherited cardiovascular diseases and sudden cardiac death (SCD) were captured using a custom probe library using the SureSelect Target Enrichment Kit for Illumina paired-end multiplexed sequencing method, (Agilent Technologies, Santa Clara, CA, USA), and sequenced using the HiSeq 1500 platform (Illumina, San Diego, CA, USA).
The investigators reported that in a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv [odds ratio (OR) 16.11) compared to the Genome Aggregation Database (gnomAD) population. In a validation cohort of 2,047 HCM probands, 32 (1.56%) carried heterozygous ALPK3tv (OR 16.17). In comparison with a cohort of 1,679 genotyped patients with HCM with and without pathogenic sarcomere gene variants (SP+ and SP−), ALPK3tv carriers had a higher prevalence of apical/concentric patterns of hypertrophy (60%) and of a short PR interval (10%).
Luis R. Lopes, MD, PhD, a Consultant Cardiologist and the lead author of the study, said, “Hypertrophic cardiomyopathy is an extremely common genetic condition. Earlier, small-scale studies suggested that variants in the ALPK3 gene could be a cause of a rare pediatric form of cardiomyopathy, but only when two abnormal copies were inherited. We have now proved that just one abnormal copy is enough to cause hypertrophic cardiomyopathy in adults, looking at a large number of patients and families. This form of inheritance (autosomal dominant) is much more prevalent, as inheriting just one abnormal copy of a gene is more likely than inheriting two. Identifying a new genetic cause is important as it opens up new possibilities for potential treatment. It also helps families who have been affected by the condition, but who did not know why, to know that a cause has been found for their specific case.” The study was published on August 21 2021 in the European Heart Journal.
Related Links:
University College London
Agilent Technologies
Illumina
Hypertrophic cardiomyopathy (HCM) is a genetic condition caused by a change or mutation in one or more genes and is passed on through families. A child of someone with HCM has a 50% chance of inheriting the condition. Most people with HCM have no symptoms or feel stable throughout their life. However, others do have symptoms. Some people find that their symptoms worsen in later life. This may be because their heart muscle has slowly become stiffer, making it harder for the heart to pump.
A large team of international scientists led by those at the University College London (London, UK) analyzed the genomes of 2,817 people with hypertrophic cardiomyopathy referred from centers in Spain, the UK, Denmark, Russia, Latvia, Brazil, and Argentina. The discovery cohort comprised 770 consecutively evaluated unrelated patients with HCM. The aim of their study was to determine the frequency of heterozygous truncating alpha-protein kinase (ALPK3) variants (ALPK3tv) in patients with HCM and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies.
From 2018 to 2020, ALPK3 was sequenced using next-generation sequencing in 4,904 consecutive unrelated probands with inherited cardiac conditions referred for molecular genetic diagnosis. Coding exons and intronic boundaries of 261 genes related to inherited cardiovascular diseases and sudden cardiac death (SCD) were captured using a custom probe library using the SureSelect Target Enrichment Kit for Illumina paired-end multiplexed sequencing method, (Agilent Technologies, Santa Clara, CA, USA), and sequenced using the HiSeq 1500 platform (Illumina, San Diego, CA, USA).
The investigators reported that in a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv [odds ratio (OR) 16.11) compared to the Genome Aggregation Database (gnomAD) population. In a validation cohort of 2,047 HCM probands, 32 (1.56%) carried heterozygous ALPK3tv (OR 16.17). In comparison with a cohort of 1,679 genotyped patients with HCM with and without pathogenic sarcomere gene variants (SP+ and SP−), ALPK3tv carriers had a higher prevalence of apical/concentric patterns of hypertrophy (60%) and of a short PR interval (10%).
Luis R. Lopes, MD, PhD, a Consultant Cardiologist and the lead author of the study, said, “Hypertrophic cardiomyopathy is an extremely common genetic condition. Earlier, small-scale studies suggested that variants in the ALPK3 gene could be a cause of a rare pediatric form of cardiomyopathy, but only when two abnormal copies were inherited. We have now proved that just one abnormal copy is enough to cause hypertrophic cardiomyopathy in adults, looking at a large number of patients and families. This form of inheritance (autosomal dominant) is much more prevalent, as inheriting just one abnormal copy of a gene is more likely than inheriting two. Identifying a new genetic cause is important as it opens up new possibilities for potential treatment. It also helps families who have been affected by the condition, but who did not know why, to know that a cause has been found for their specific case.” The study was published on August 21 2021 in the European Heart Journal.
Related Links:
University College London
Agilent Technologies
Illumina
Latest Pathology News
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







